CIK: 0001553936
Total reported value
$30.9M
Reporting period: 2025-09-30 · Number of holdings: 4
TYBOURNE CAPITAL MANAGEMENT (HK) LTD disclosed 4 holdings in its latest 13F filing for the period ending 2025-09-30, with total reported value of $30.9M and a quarterly turnover rate of 96.8%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "T"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add FBRX
0.0% $7.0M
Add TSHA
-9.6% $7.0M
Trim ZNTL
-35.0% -$76.9K
Sold out 00445A100
New buy ALMS
Sold out BCYC
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TSHA | Taysha Gene Therapies INC | Stock-Other | 39.11% | +17.28% | -9.65% | |
| 2 | FBRX | Forte Biosciences INC | Stock-Other | 38.15% | +17.73% | — | |
| 3 | ALMS | Alumis INC | Stock-Other | 18.05% | +18.05% | NEW | |
| 4 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 4.69% | -1.80% | -34.95% |
Performance for Q3 2026
+40.5%
Performance Last 4 Quarters
+322.6%
Based on 61% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2025-09-30 | 4 | $30.9M | 97 | |
| 2025-06-30 | 6 | $34.5M | 0 | |
| 2025-03-31 | 5 | $23.6M | 100 | |
| 2024-12-31 | 37 | $398.4M | 0 | |
| 2024-09-30 | 34 | $356.7M | 0 | |
| 2024-06-30 | 40 | $491.7M | 0 | |
| 2024-03-31 | 41 | $584.9M | 0 | |
| 2023-12-31 | 39 | $671.2M | 0 | |
| 2023-09-30 | 41 | $715.7M | 0 | |
| 2023-06-30 | 49 | $925.3M | 0 | |
| 2023-03-31 | 49 | $993.2M | 0 | |
| 2022-12-31 | 27 | $1.0B | 0 | |
| 2022-09-30 | 26 | $1.0B | 0 | |
| 2022-06-30 | 27 | $1.4B | 0 | |
| 2022-03-31 | 30 | $1.7B | 0 | |
| 2021-12-31 | 26 | $3.4B | 0 | |
| 2021-09-30 | 24 | $4.0B | 0 | |
| 2021-06-30 | 29 | $4.7B | 98 | |
| 2021-03-31 | 32 | $4.6B | 66 | |
| 2020-12-31 | 31 | $4.8B | 59 | |
| 2020-09-30 | 29 | $4.1B | 66 | |
| 2020-06-30 | 21 | $3.3B | 100 | |
| 2020-03-31 | 21 | $2.7B | 91 | |
| 2019-12-31 | 13 | $2.6B | 49 | |
| 2019-09-30 | 12 | $2.3B | 40 | |
| 2019-06-30 | 13 | $2.8B | 53 | |
| 2019-03-31 | 11 | $2.6B | 42 | |
| 2018-12-31 | 9 | $2.2B | 40 | |
| 2018-09-30 | 9 | $2.3B | 36 | |
| 2018-06-30 | 8 | $2.2B | 54 | |
| 2018-03-31 | 8 | $2.0B | 41 | |
| 2017-12-31 | 5 | $1.6B | 89 | |
| 2017-09-30 | 6 | $1.3B | 93 | |
| 2017-06-30 | 7 | $2.2B | 45 | |
| 2017-03-31 | 9 | $2.2B | 44 | |
| 2016-12-31 | 10 | $2.1B | 64 | |
| 2016-09-30 | 9 | $2.0B | 16 | |
| 2016-06-30 | 10 | $1.9B | 97 | |
| 2016-03-31 | 9 | $1.5B | 51 | |
| 2015-12-31 | 8 | $1.3B | 44 | |
| 2015-09-30 | 8 | $1.4B | 68 | |
| 2015-06-30 | 8 | $1.2B | 72 | |
| 2015-03-31 | 10 | $1.1B | 56 | |
| 2014-12-31 | 11 | $1.1B | 16 | |
| 2014-09-30 | 11 | $1.0B | 50 | |
| 2014-06-30 | 11 | $1.1B | 72 | |
| 2014-03-31 | 13 | $878.0M | 57 | |
| 2013-12-31 | 12 | $915.4M | 46 | |
| 2013-09-30 | 13 | $842.5M | 91 | |
| 2013-06-30 | 13 | $671.4M | 0 |
Tybourne Capital Management (hk) LTD's most significant position changes for 2025-09-30: Sold out: Acelyrin INC; New buy: Alumis INC (ALMS); Sold out: Bicycle Therapeutics Plc-adr (BCYC); Add: Forte Biosciences INC (FBRX) — shares 0.00%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | FBRX | Forte Biosciences INC | +17.7% | — | Add |
| 2 | TSHA | Taysha Gene Therapies INC | +17.3% | -9.65% | Unchanged |
| 3 | ZNTL | Zentalis Pharmaceuticals INC | -1.8% | -34.95% | Unchanged |
| 4 | ✓ | Acelyrin INC | — | EXIT | Sold out |
| 5 | ALMS | Alumis INC | — | NEW | New buy |
| 6 | BCYC | Bicycle Therapeutics Plc-adr | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2025-09-30 | 2025-11-06 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-01 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-04 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-25 | Amendment | View on EDGAR |
| 2021-12-31 | 2022-01-26 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-10-27 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-07-22 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-04-13 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-11 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-09 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-13 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-24 | Amendment | View on EDGAR |
| 2014-12-31 | 2015-02-13 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-14 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-01-28 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-14 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2013-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001619125
Total reported value
$30.9M
10 stks
2022-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001552200
Total reported value
$31.0M
2 stks
2019-12-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001912675
Total reported value
$31.0M
2 stks
2022-09-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001318153
Total reported value
$2.9M
3 stks
2024-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Zentalis Pharmaceuticals INC
CIK 0001595430
Total reported value
$1.4B
17 stks
2026-03-31
1 of the top 5 holdings overlap, including Alumis INC
CIK 0001668029
Total reported value
$97.0M
8 stks
2026-03-31
1 of the top 5 holdings overlap, including Alumis INC